Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00639262 · ClinicalTrials.gov registry record · Phase 1
Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00639262 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 35 participants.
The verdict
NCT00639262, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance radiation response. This study will test the combination of Sorafenib™ and radiation therapy with or without temozolomide to determine tolerance of the combined treatments. Defining safe dosing of Sorafenib™ in this combination therapy will be achieved.
Interventions
- DRUG Temozolomide
- RADIATION Radiotherapy
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00639262
The ClinicalTrials.gov registry entry for NCT00639262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT00639262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00639262 about?
NCT00639262 is a clinical study titled "Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors". Sorafenib™ has the potential to inhibit tumor growth, tumor angiogenesis , and enhance radiation response. This study will test the combination of Sorafenib™ and radiation therapy with or without temozolomide to determine tolerance of the combined treatments. Defining safe dosing of Sorafenib™ in th...
What is the current status of trial NCT00639262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2008-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00639262?
The interventions under investigation include: Temozolomide (DRUG), Radiotherapy (RADIATION), Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00639262?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.